Bayer reports phase I results for prostate cancer therapy Feb 27, 2026 12:48PM
Bayer's XOFIGO plus enzalutamide reduces death risk by 24% in prostate cancer Feb 26, 2026 11:28AM
Bayer's asundexian reduces stroke risk by 26% in phase III trial Feb 5, 2026 12:15PM